Prediabetes is a reversible warning stage before type 2 diabetes, affecting millions of Indians. Early detection through blood tests and timely lifestyle changes can significantly ... Aug 13
Obesity is a complex chronic disease characterized by excessive body fat and is often linked to conditions such as diabetes and hypertension. GLP1 receptor agonists ... Aug 10
Prediabetes is a reversible metabolic warning stage before type 2 diabetes, particularly urgent in India. Early screening, lifestyle modification, and timely medical guidance can prevent ... Jul 29
Fatty liver and diabetes share insulin resistance as a common root cause, creating a harmful cycle that millions of Indian patients face silently. Early awareness, ... Jun 18
Enables commercialisation for the first two entrants in the world’s second-largest semaglutide market.... May 05
OneSource Speciality Pharma Limited today announced that its partner Orbicular Pharmaceutical Technologies , together with its U.S.-based front-end partner, has secured tentative U.... Apr 23
MSN Laboratories today announced the launch of SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). ... Apr 15
A medication initially designed to regulate blood sugar eventually transformed the management of obesity. Now it may hold clues to understanding the biological roots of ... Mar 10
Medical innovation has provided powerful tools to address one of the world’s most pressing health challenges. But the path to lasting wellness still requires ... Mar 07
In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (8.9 kg ;9.2%) compared to 11.0 lbs (5 ... Feb 28
The debate between pharmacotherapy and surgery will continue, but patients deserve nuanced guidance grounded in evidence, not trends... Feb 26
... Feb 11
OneSource Speciality Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended December 31, 2025 (Q3FY26).... Jan 24
As India struggles with rising obesity and diabetes, MASLD stands as a mirror reflecting broader metabolic dysfunction.... Jan 17
As the patent clock ticks towards 2026, both Novo and Lilly are likely to intensify their efforts in expanding supply chains, boosting physician engagement, and ... Nov 14
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ... Oct 16
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ... Oct 15
Long-term effects of GLP-1 medications remain under investigation, and shifting to easy-to-use pens removes barriers but not risks.... Aug 16
Generic semaglutide could ultimately become not just an alternative, but the new standard driven by precision manufacturing, scaled access, and cost redefined.... Aug 11
SCHOTT becomes the first in India to locally produce high-precision glass tubing for syringes and cartridges in its manufacturing facility in Jambusar, Gujarat.... Aug 07
As India confronts an alarming rise in obesity and related conditions like type 2 diabetes, cardiovascular disease, and polycystic ovarian syndrome, the spotlight on medical ... Jun 25
... May 12
A somewhat promising era of weight management has arrived. Ozempic and Mounjaro are no longer just for diabetes. But it’s not all magic. Risks, ... May 10
The WHO's endorsement of GLP-1 receptor agonists represents a significant development in the global fight against obesity.... May 08
With innovations like DeepDKD, the healthcare narrative could shift from reactive to preventive, from managing damage to averting it entirely.... May 08
-Advertisements-
-23-300x250.png)
.jpeg)
Tuesday, October 27, 2026
.jpg)
.jpg)
.jpeg)
.jpeg)
.png)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
